- Home
- ACIU vs PRQR Comparison
ACIU vs PRQR Comparison
Compare ACIU & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACIU | PRQR |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | Switzerland | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 250.7M |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACIU | PRQR |
|---|---|---|
| Price | $3.01 | $2.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $10.00 | $8.14 |
| AVG Volume (30 Days) | ★ 1.4M | 621.8K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,482,957.00 | ★ $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $738.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $1.07 |
| 52 Week High | $4.00 | $3.10 |
Technical Indicators
Market Signals| Indicator | ACIU | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 49.00 |
| Support Level | $2.87 | $2.15 |
| Resistance Level | $3.45 | $2.49 |
| Average True Range (ATR) | 0.31 | 0.18 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 38.09 | 52.17 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.